Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

2.46
+0.04381.81%
Volume:7K
Turnover:18.27K
Market Cap:62.58M
PE:-1.28
High:2.46
Open:2.38
Low:2.38
Close:2.42
52wk High:5.83
52wk Low:1.22
Shares:25.40M
Float Shares:11.48M
Volume Ratio:0.52
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9304
EPS(LYR):-1.9100
ROE:-207.94%
ROA:-92.30%
PB:3.34
PE(LYR):-1.29

Loading ...

Sumitomo Backs $1m Exploration Push at SER’s Bulimba Gold Project

TIPRANKS
·
Jul 02

Serina Therapeutics initiated with a Buy at BTIG

TIPRANKS
·
Jul 01

Gannet Biochem and Serina Therapeutics Enter Development Partnership Supporting Ser-252 Program

THOMSON REUTERS
·
Jun 30

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

GlobeNewswire
·
Jun 25

Serina Therapeutics Shareholders Approved Increase in Authorized Common Shares to 125 Million

Reuters
·
Jun 25

Serina Therapeutics director Jay Venkatesan acquires 589 common shares valued at $1,048.42

Reuters
·
Jun 23

Serina Therapeutics director Karen J. Wilson acquires common shares worth $17,894.50

Reuters
·
Jun 15

Serina Therapeutics director Karen J. Wilson acquires USD 37,000 common shares

Reuters
·
May 27

Serina Therapeutics director Richard Peter Marshall buys USD 20,102 common shares

Reuters
·
May 23

Serina Therapeutics files to sell 16.45M shares of common stock for holders

TIPRANKS
·
May 23

Serina Therapeutics Inc - Files to Register Resale of up to 16.5 Mln Common Shares by Selling Stockholder- SEC Filing

THOMSON REUTERS
·
May 23

Serina Therapeutics (SER) Gets a Buy from JonesTrading

TIPRANKS
·
May 18

Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks

TIPRANKS
·
May 16

Serina Therapeutics: Q1 EPS $-0.58

THOMSON REUTERS
·
May 15

Serina Therapeutics: Ser-252 Phase 1B Registrational Study Underway in Advanced Parkinson's Disease; Tfl Data Targeted for H1 2027

THOMSON REUTERS
·
May 15

Serina Therapeutics Q1 FY26 net loss widens to $6.9 million from Q1 FY25

Reuters
·
May 15

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

GlobeNewswire
·
May 04

SER Industries Gets BSE's Approval for Name Change

MT Newswires Live
·
Apr 22

Serina Therapeutics names Srini Tenjarla chief technology officer

Reuters
·
Apr 22

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

GlobeNewswire
·
Apr 20